Literature DB >> 25257573

Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium.

Jenny Louise Anderson1, Rémi Fromentin, Giulio Maria Corbelli, Lars Østergaard, Anna Laura Ross.   

Abstract

Biomedical research has led to profound advances in the treatment of HIV infection. Combination antiretroviral therapy (ART) now provides the means to readily control viral infection, and people living with HIV who receive timely and effective ART can expect to benefit from a life expectancy comparable to uninfected individuals. Nevertheless, despite effective treatment, ART does not fully restore the immune system and importantly HIV persists indefinitely in latent reservoirs, resulting in the need for life-long treatment. The challenges and limits of life-long treatment have spurred significant scientific interest and global investment into research towards an HIV cure. The International AIDS Society (IAS) 2014 Towards an HIV cure symposium brought together researchers and community to discuss the most recent advances in our understanding of latency and HIV reservoirs, and the clinical approaches towards an HIV cure under current investigation. This report summarizes and reviews some of the major findings discussed during the symposium.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25257573      PMCID: PMC4287112          DOI: 10.1089/AID.2014.0236

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  35 in total

Review 1.  HDAC inhibitors in HIV.

Authors:  Fiona Wightman; Paula Ellenberg; Melissa Churchill; Sharon R Lewin
Journal:  Immunol Cell Biol       Date:  2011-11-15       Impact factor: 5.126

2.  BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.

Authors:  Camellia Banerjee; Nancie Archin; Daniel Michaels; Anna C Belkina; Gerald V Denis; James Bradner; Paola Sebastiani; David M Margolis; Monty Montano
Journal:  J Leukoc Biol       Date:  2012-07-16       Impact factor: 4.962

3.  HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.

Authors:  Nancy M Archin; Rosalie Bateson; Manoj K Tripathy; Amanda M Crooks; Kuo-Hsiung Yang; Noelle P Dahl; Mary F Kearney; Elizabeth M Anderson; John M Coffin; Matthew C Strain; Douglas D Richman; Kevin R Robertson; Angela D Kashuba; Ronald J Bosch; Daria J Hazuda; Joann D Kuruc; Joseph J Eron; David M Margolis
Journal:  J Infect Dis       Date:  2014-03-11       Impact factor: 5.226

4.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Authors:  Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard
Journal:  Lancet HIV       Date:  2014-09-15       Impact factor: 12.767

7.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.

Authors:  Amarendra Pegu; Zhi-yong Yang; Jeffrey C Boyington; Lan Wu; Sung-Youl Ko; Stephen D Schmidt; Krisha McKee; Wing-Pui Kong; Wei Shi; Xuejun Chen; John-Paul Todd; Norman L Letvin; Jinghe Huang; Martha C Nason; James A Hoxie; Peter D Kwong; Mark Connors; Srinivas S Rao; John R Mascola; Gary J Nabel
Journal:  Sci Transl Med       Date:  2014-07-02       Impact factor: 17.956

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

10.  Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Authors:  Datsen George Wei; Vicki Chiang; Elizabeth Fyne; Mini Balakrishnan; Tiffany Barnes; Michael Graupe; Joseph Hesselgesser; Alivelu Irrinki; Jeffrey P Murry; George Stepan; Kirsten M Stray; Angela Tsai; Helen Yu; Jonathan Spindler; Mary Kearney; Celsa A Spina; Deborah McMahon; Jacob Lalezari; Derek Sloan; John Mellors; Romas Geleziunas; Tomas Cihlar
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more
  15 in total

Review 1.  Global strategies are required to cure and eliminate HBV infection.

Authors:  Peter Revill; Barbara Testoni; Stephen Locarnini; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-24       Impact factor: 46.802

Review 2.  Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?

Authors:  Wasim Abbas; Muhammad Tariq; Mazhar Iqbal; Amit Kumar; Georges Herbein
Journal:  Viruses       Date:  2015-03-31       Impact factor: 5.048

3.  The latest science from the IAS Towards an HIV Cure Symposium: 16-17 July 2016, Durban, South Africa.

Authors:  Jaclyn Mann; Alexander O Pasternak; Ann Chahroudi; Jerome A Singh; Anna Laura Ross
Journal:  J Virus Erad       Date:  2016-10-05

4.  The social value of candidate HIV cures: actualism versus possibilism.

Authors:  Regina Brown; Nicholas Greig Evans
Journal:  J Med Ethics       Date:  2016-07-08       Impact factor: 2.903

5.  Genome modification of CXCR4 by Staphylococcus aureus Cas9 renders cells resistance to HIV-1 infection.

Authors:  Qiankun Wang; Shuliang Chen; Qiaoqiao Xiao; Zhepeng Liu; Shuai Liu; Panpan Hou; Li Zhou; Wei Hou; Wenzhe Ho; Chunmei Li; Li Wu; Deyin Guo
Journal:  Retrovirology       Date:  2017-11-15       Impact factor: 4.602

6.  Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B.

Authors:  Miriam Rosás-Umbert; Beatriz Mothe; Marc Noguera-Julian; Rocío Bellido; Maria C Puertas; Jorge Carrillo; C Rodriguez; Núria Perez-Alvarez; Patricia Cobarsí; Carmen E Gomez; Mariano Esteban; Jose Luis Jímenez; Felipe García; Julià Blanco; Javier Martinez-Picado; Roger Paredes; Christian Brander
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

7.  HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02).

Authors:  Beatriz Mothe; Miriam Rosás-Umbert; Pep Coll; Christian Manzardo; Maria C Puertas; Sara Morón-López; Anuska Llano; Cristina Miranda; Samandhy Cedeño; Miriam López; Yovaninna Alarcón-Soto; Guadalupe Gómez Melis; Klaus Langohr; Ana M Barriocanal; Jessica Toro; Irene Ruiz; Cristina Rovira; Antonio Carrillo; Michael Meulbroek; Alison Crook; Edmund G Wee; Jose M Miró; Bonaventura Clotet; Marta Valle; Javier Martinez-Picado; Tomáš Hanke; Christian Brander; José Moltó
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

Review 8.  Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.

Authors:  Gina M Graziani; Jonathan B Angel
Journal:  J Int AIDS Soc       Date:  2015-11-09       Impact factor: 5.396

Review 9.  Which New Health Technologies Do We Need to Achieve an End to HIV/AIDS?

Authors:  Glenda E Gray; Fatima Laher; Tanya Doherty; Salim Abdool Karim; Scott Hammer; John Mascola; Chris Beyrer; Larry Corey
Journal:  PLoS Biol       Date:  2016-03-02       Impact factor: 8.029

10.  When to start paediatric testing of the adult HIV cure research agenda?

Authors:  Seema K Shah
Journal:  J Med Ethics       Date:  2016-06-03       Impact factor: 5.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.